Abzena (San Diego) Inc

Activities: Manufacturing Ingredients Regulatory Research & Development Analysis

Trending Articles

  1. Payload cleaning and analytics: overcoming the challenges of payload cleaning and analytics in ADC manufacturing 29 January 2026 | Virtual
  2. Grifols receives US FDA approval for new fibrinogen concentrate: FESILTY (fibrinogen, human-chmt) The fibrinogen concentrate complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Integrating responsible AI into ESG strategies Today, artificial intelligence (AI) is changing the way businesses operate, but there’s no denying that it presents both opportunities and risks
  4. ten23 health QC lab to support commercial product testing for US customer following FDA approvals This pivotal regulatory milestone enables FDA-compliant release and stability testing for injectable drug products throughout the clinical and commercial phases, in addition to...
  5. From data to decisions: applying criticality and failure probability in process risk mitigation This article presents an exploration of how structured, data-based methods enhance quality control, optimise specifications and improve process robustness throughout the...

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

Related Content

Research & Development

Biologics at a turning point: complexity, AI and the road to 2026

Despite rapid change, the growing complexity of biologics and the rise of AI-driven design are reinforcing the increasing need for deep scientific expertise and innovation leadership, says Campbell Bunce (CB), Chief Scientific Officer at Abzena
Manufacturing

Abzena advances ADC development with ThioBridge conjugation technology

Next-generation conjugation delivers greater stability, potency and control for targeted cancer therapeutics
Manufacturing

Abzena and Mabqi announce strategic partnership to offer integrated discovery through development solution

This collaboration will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution
Manufacturing

Driving ADC innovation with complex chemistry solutions

Abzena’s tailored chemistry expertise enables scalable, high-quality bioconjugate development from discovery to GMP production
Manufacturing

Streamlining bioconjugation for next-generation ADC development

Abzena’s proprietary ThioBridge™ technology delivers precision, scalability, and enhanced stability for antibody-drug conjugates
Research & Development

Orion secures exclusive license to Abzena’s CHAb-designed oncology antibody

The deal strengthens Orion’s cancer R&D pipeline with a de-risked monoclonal antibody developed using Abzena’s proprietary Composite Human Antibody (CHAb) and AbZelectPRO platforms
Regulatory

Abzena advances immunogenicity risk assessment in biologic drug development

New white paper explores how early testing helps predict and prevent unwanted immune responses in therapeutic proteins
Subscribe now